Skip to main content

Table 1 Descriptive statistics for signalment and demographics of dogs enrolled on Day 0 as veterinary patients and included in the effectiveness evaluable population

From: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Demographics of study dogs European nematode field study
IP: Credelio Plus (n = 278) CP: Afoxolaner + MO (n = 117)
Purebred, n (%) 160 (57.6) 60 (51.3)
Mixed breed, n (%) 118 (42.4) 57 (48.7)
Age, mean (months) 58.8 51.8
Age, range (months) 1.9–180.0 2.3–156
Bodyweight, mean (kg) 21.3 22.7
Bodyweight, range (kg) 3.5–53.3 2.8–70.0
Male, n (%) 143 (51.4) 67 (57.3)
Female, n (%) 135 (48.6) 50 (42.7)
Coat length, n (%)
 Short 126 (45.3) 52 (44.4)
 Medium 123 (44.2) 56 (47.9)
 Long 29 (10.4) 9 (7.7)
Number of dogs in each country (%)
 France 130 (46.8) 52 (44.4)
 Germany 26 (9.4) 9 (7.7)
 Hungary 122 (43.9) 56 (47.9)
Sleeping location, n (%)
 Inside 75 (27.0) 27 (23.1)
 Outside 203 (73.0) 90 (76.9)
Presence of fleas or ticks, n (%)
 No 182 (65.5) 79 (67.5)
 Yes 96 (34.5) 38 (32.5)
  1. IP Investigational product; combination tablets of lotilaner + milbemycin oxime (MO), marketed as Credelio Plus (Elanco Animal Health, Greenfield, IN, USA); CP control product; combination tablets of afoxolaner + MO, marketed as Nexgard Spectra (Boehringer Ingelheim, Ingelheim am Rhein, Germany)